The researchers found that at week 56, the mean percentage change from baseline in body mass index was −5.8% and 1.6% with liraglutide and placebo, respectively. (HealthDay News) — Liraglutide ...
The analyses included 3389 adults with a body mass index of at least 30.0kg/m2 who initiated semaglutide or liraglutide for obesity or type 2 diabetes. (HealthDay News) — For patients with ...
HealthDay News — For patients with obesity receiving semaglutide or liraglutide, weight reduction at one year is associated with medication active agent, dosage, treatment indication ...
Weight reduction at 1 year linked to medication active agent, dosage, treatment indication, persistence of coverage. (HealthDay News) — For patients with obesity receiving semaglutide or ...
After hours: September 20 at 6:54 PM EDT ...
A Cleveland Clinic study identified factors affecting weight loss in obesity patients using semaglutide or liraglutide. Key factors included medication type, dosage, treatment purpose, and adherence.
This week on Pipeline Moves, we kick off by looking at Novo Nordisk’s completion of a Phase III trial of liraglutide in children aged under 12. Meanwhile, Pfizer’s maplirpacept saw its transition ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback